Improving treatments for myeloid leukemia in children with Down syndrome
Enhancing treatments for myeloid leukemia associated with Down syndrome
This study is looking at how a common leukemia treatment works for kids with Down syndrome, focusing on how the leukemia cells interact with their bone marrow, to find better ways to help them respond to treatment and lower the chances of the cancer coming back.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wayne State University NIH-funded |
| Lab location | 1 site (Detroit, United States) |
| Project ID | NIH-10878451 on NIH RePORTER |
What this research studies
This research investigates how myeloid leukemia, particularly in children with Down syndrome, responds to treatments involving cytarabine. It focuses on understanding the interactions between leukemia cells and the bone marrow environment, specifically how endothelial cells influence treatment effectiveness and the potential for relapse. By studying these interactions, the research aims to uncover the molecular mechanisms that contribute to the high survival rates observed in these patients. The ultimate goal is to enhance treatment strategies and reduce the risk of relapse for children with this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years diagnosed with myeloid leukemia and Down syndrome.
Not a fit: Patients with myeloid leukemia who do not have Down syndrome may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments and improved survival rates for children with myeloid leukemia associated with Down syndrome.
How similar studies have performed: Previous research has shown promising results in understanding leukemia treatment responses, but this specific focus on Down syndrome is relatively novel.
Where this research is happening
Detroit, United States
- Wayne State University — Detroit, United States (Active)
Researchers
- Principal investigator: Taub, Jeffrey Warren — Wayne State University
- Study coordinator: Taub, Jeffrey Warren
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.